| Literature DB >> 26467359 |
Ruifeng Liu1, Lianfeng Chen, Wei Wu, Houzao Chen, Shuyang Zhang.
Abstract
OBJECTIVE: Proteolytic enzymes possibly contribute to coronary artery ectasia (CAE). This study aimed to determine whether neutrophils, neutrophil serine proteases (NSPs), and their endogenous inhibitors participated in the pathological process of CAE.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26467359 PMCID: PMC5336701 DOI: 10.5152/akd.2015.6072
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Clinical characteristics of the study patients
| Variables | CAE (n=30) | CAD (n=30) | Control (n=29) | |
|---|---|---|---|---|
| Age, years | 62.80±10.17 | 60.07±9.21 | 63.96±9.59 | 0.286 |
| Gender, male/female | 20/10 (66.67%) | 21/9 (70.00%) | 15/14 (51.72%) | 0.304 |
| Diabetes mellitus | 11/19 (36.67%) | 13/17 (43.33%) | 10/19 (33.33%) | 0.765 |
| Glucose, mmol/L | 6.12±1.56 | 6.21±1.73 | 5.96±1.29 | 0.957 |
| Hypertension | 24/6 (80.00%) | 21/9 (70.00%) | 20/9 (68.97%) | 0.570 |
| Systolic blood pressure, mm Hg | 132.57±17.96 | 132.13±17.07 | 129.86±16.77 | 0.813 |
| Diastolic blood pressure, mm Hg | 79.33±12.14 | 74.93±14.56 | 75.55±11.32 | 0.357 |
| Heart rate, per minute | 71.37±10.06 | 70.83±9.02 | 72.86±11.63 | 0.736 |
| Family history of CAD | 7/23 (23.33%) | 12/18 (40.00%) | 3/26 (10.34%) | 0.030 |
| Family history of type 2 diabetes mellitus | 2/28 (6.67%) | 6/24 (20.00%) | 3/26 (10.34%) | 0.269 |
| Smoking | 10/20 (33.33%) | 15/15 (50.00%) | 9/20 (31.03%) | 0.259 |
| Alcohol consumption | 6/24 (20.00%) | 10/20 (33.33%) | 9/20 (31.03%) | 0.471 |
| TC, mmol/L | 1.66±1.22 | 1.73±0.84 | 1.50±1.05 | 0.696 |
| HDL cholesterol, mmol/L | 1.08±0.31 | 1.08±0.39 | 1.15±0.32 | 0.270 |
| LDL cholesterol, mmol/L | 2.39±0.80 | 2.50±0.87 | 2.31±0.78 | 0.701 |
| TG, mmol/L | 1.66±1.22 | 1.73±0.84 | 1.50±1.05 | 0.139 |
| Body mass index, kg/m2 | 26.45±3.83 | 25.51±3.77 | 25.16±2.98 | 0.387 |
| Hs-CRP, mg/L | 2.90±3.60 | 2.25±2.24 | 2.16±2.61 | 0.542 |
| Leukocytes, 103/µL | 6.26±1.26 | 6.47±1.62 | 6.36±1.37 | 0.852 |
| Neutrophils | 3.74±1.00 | 3.99±1.28 | 4.04±1.23 | 0.560 |
| Lymphocytes | 1.90±0.60 | 1.85±0.58 | 1.74±0.52 | 0.523 |
| Monocytes | 0.39±0.14 | 0.39±0.13 | 0.37±0.12 | 0.765 |
| Neutrophil /lymphocyte ratio | 2.16±0.87 | 2.27±0.73 | 2.60±1.30 | 0.545 |
| ALT, U/L | 26.07±20.76 | 28.70±27.03 | 26.10±14.23 | 0.844 |
| BUN, mmol/L | 6.11±1.73 | 5.50±1.93 | 5.75±1.60 | 0.246 |
| Creatinine, µmol/L | 85.67±29.64 | 78.87±18.50 | 73.69±19.53 | 0.310 |
| Ectatic vessels of CAE | ||||
| LM | 3/27 (10.00%) | |||
| LAD | 11/19 (36.67%) | |||
| LCX | 18/12 (60.00%) | |||
| RCA | 20/10 (66.67%) |
P values for comparison among and between the groups. The significance level was 0.05. CAD - coronary artery disease; CAE - coronary artery ectasia; Control - control group; HDL-c - high-density lipoprotein cholesterol; LAD - left anterior descending coronary artery; LCX - left circumflex coronary artery; LDL-c - low-density lipoprotein cholesterol; LM - left main coronary artery; RCA - right coronary artery; TC - total cholesterol; TG - triglyceride
The three NSP and elastin fibre degradation production
| Variables | CAE (n=30) | CAD (n=30) | Control (n=29) | ||||
|---|---|---|---|---|---|---|---|
| HNE, ng/mL | 34.86±10.17 | 26.66±4.24 | 26.22±4.23 | 0.000 | 0.000 | 0.000 | 0.387 |
| CG, pg/mL | 659.82±262.33 | 544.08±132.38 | 507.59±180.17 | 0.031 | 0.027 | 0.016 | 0.184 |
| PR3, ng/mL | 1.30±0.33 | 1.22±0.19 | 1.24±0.20 | 0.376 | 0.574 | 0.927 | 0.628 |
| sElastin, ng/mL | 22.67±11.71 | 13.86±5.46 | 10.13±1.03 | 0.000 | 0.001 | 0.000 | 0.380 |
P values for comparison among groups and comparison between groups using the LSD method: P1, CAE group vs. CAD group; P2, CAE group vs. Control group; P3, CAD group vs. Control group. The significance level was 0.05. CAD - coronary artery disease; CAE - coronary artery ectasia; Control - control group; CG - cathepsin G; HNE - human neutrophil elastase; PR3 - proteinase 3; sElastin - soluble elastin
The main circulating NSP inhibitors
| Variables | CAE (n=30) | CAD (n=30) | Control (n=29) | ||||
|---|---|---|---|---|---|---|---|
| α1-PI, ng/mL | 423.22±178.61 | 207.70±37.08 | 193.32±36.42 | 0.000 | 0.000 | 0.000 | 0.610 |
| α2-MG, mg/mL | 5.28±2.30 | 3.99±1.65 | 3.31±1.47 | 0.001 | 0.034 | 0.000 | 0.075 |
| SLPI, pg/mL | 329.15±264.25 | 406.40±337.48 | 289.52±97.95 | 0.202 | 0.101 | 0.561 | 0.116 |
| Elafin, pg/mL | 170.00±163.02 | 197.80±143.11 | 156.64±99.71 | 0.510 | 0.510 | 0.491 | 0.198 |
P values for comparison among groups and comparison between groups using the LSD method: P1, CAE group vs. CAD group; P2, CAE group vs. Control group; P3, CAD group vs. Control group. The significance level was 0.05. α1-PI - α1-protease inhibitor; α2-MG - α2-macroglobulin; CAD - coronary artery disease; CAE - coronary artery ectasia; Control - control group; SLPI - secretory leucoprotease inhibitor
Two activation markers for neutrophils and three classic neutrophil activators
| Variables | CAE (n=30) | CAD (n=30) | Control (n=29) | ||||
|---|---|---|---|---|---|---|---|
| MPO, ng/mL | 5.25±3.86 | 1.38±0.52 | 1.89±1.07 | 0.000 | 0.000 | 0.000 | 0.291 |
| LTF, ng/mL | 182.92±103.75 | 92.01±44.52 | 79.92±38.98 | 0.000 | 0.000 | 0.000 | 0.504 |
| IL-8, pg/mL | 42.46±4.48 | 41.77±2.12 | 40.70±4.47 | 0.071 | 0.712 | 0.051 | 0.450 |
| TNF-α, pg/mL | 48.18±8.34 | 47.78±7.42 | 46.40±6.98 | 0.039 | 0.657 | 0.030 | 0.026 |
| Endotoxin positive rate | 0/30 (0.00%) | 0/30 (0.00%) | 0/29 (0.00%) |
P values for comparison among groups and comparison between groups using the LSD method: P1, CAE group vs. CAD group; P2, CAE group vs. Control group; P3, CAD group vs. Control group. The significance level was 0.05. CAD - coronary artery disease; CAE - coronary artery ectasia; Control - control group; IL-8 - interleukin-8; LTF - lactoferrin; MPO - myeloperoxidase; TNF-α - tumor necrosis factor-α